.png)
Biodefense Market By Product - Global Industry Analysis and Forecast to 2022
Published On : November 2017 Pages : 132 Category: Defence & Security Report Code : HC11341
SEGMENTS & REGIONS:
- Regions: North America, Europe, Asia- Pacific, Latin America, Middle East & Africa
Industry Trend Analysis
In 2017, the global biodefense market was evaluated around USD 7.98 billion and is expected to reach approximately USD 16.16 billion by 2022 while registering itself at a compound annual growth rate (CAGR) of 7.32% over the forecast period owing to technological developments in pathogen detection method in the forensic department. A few of the modern technologies employed in biodefense are nanotechnology, database management systems, advanced detector hardware, and gene chips. The rising vaccines production, quick diagnostic procedures, superior detection and forensic therapies, and prophylactics are amongst the crucial factors anticipated to reinforce the biodefense capabilities around the globe over the projected period. Escalating investment by the local government in developed economies, like the Europe and the United States, for biodefense awareness, is expected to boost the growth during the forecast years. According to the report issued by the Centre for Research on Innovation and Science Policy, it was affirmed that the number of grants owed by the National Institutes of Health (NIH) for the progress of bioweapon agents, like anthrax, plague, glanders, brucellosis, and tularemia, had augmented by 15 times over the years, 1996-2001. Due to the augment in the number of co-owned and foreign-owned patents, a number of international associations, subcontracting, and technological collaboration agreements are increasing, which are hence anticipated to drive the market demand in the approaching few years. Furthermore, rising government intervention concerning advancing different initiatives, like the BioShield initiative was undertaken during 2004, and producing payments for private biotech firms to manufacture and develop new vaccines alongside CDC-defined category A bioterrorism threats, like tularemia, botulism, and viral hemorrhagic fevers such as Ebola. The ensuing market opportunity has contributed to collaborations among the private players as well as with several international biotechnology firms in regions, like Japan, France, Denmark, Belgium, Austria, the UK, and the Netherlands, to expand countermeasures beside biological threat agents.
Product Outlook and Trend Analysis
In 2017, Anthrax was the leading application section and reported for a market share of around 31.3%.The rising interest, as well as attempts of private players in escalating the product range providing to anthrax prevention, is expected to drive the industry growth in the approaching years. Rising government investments in the United States to produce and stockpile adequate vaccines against anthrax during various programs, like Biomedical Advanced Research and Development Authority (BARDA), BioShield Legislation, and Joint Program Executive Office for Biological and Chemical Defense, is initiating commercial opportunities for this field. The other products section reported for approximately 15% of the overall market during 2017 and is anticipated to grow at a compound annual growth rate of around 8.3% during forecast period. The viral hemorrhagic section is recognized as the most productive sector. Rapid ascend in R&D funding after the Ebola outbreaks over 2017-2017 and rising awareness concerning the prospective of the virus being utilized as a bio-weapon assigns to the abovementioned conclusion. The radiation section is also anticipated to experience rapid expansion over the forecast years. The global market is propelled by expansion in the research and development initiatives subsequent to the nuclear crisis in Japan.
Regional Outlook and Trend Analysis
In 2017, North American market appeared as the major segment reporting for over half of the global industry. Government initiatives concerning to the funding for genetic defense mechanism is a key factor pushing the expansion of the market. Though, fluctuations in financial support owing to altering government regulations might hamper demand over the forecast years. Asia Pacific region is anticipated to experience a major demand owing to rising investments in the R&D segment. Japan and Australia are a couple of the most developed Asia Pacific regional markets. The widespread vaccine production facilities offer across Japan along with the existence of advanced healthcare infrastructure in the nation is leading to its robust industry position.
Competitive Outlook and Trend Analysis
Global biodefense market is comparatively less competitive owing to dedicated nature of the products, and small commercial products demand. The major industry players are Xoma Corporation, PharmAthene, Inc., Emergent BioSolutions, Inc., Dynavax Technologies Corporation, SIGA Technologies, Inc., Elusys Therapeutics, Inc., Ichor Medical Systems, Inc., DynPort Vaccine Company, LLC, Cleveland BioLabs, Inc., Bavarian Nordic, Achaogen, Inc., Nanotherapeutics, Inc., and Alnylam Pharmaceuticals, Inc.
The global biodefense market is segmented as follows –
By Product
- Anthrax
- Smallpox
- Botulism
- Radiation/ nuclear defense
- Others
By Region
- North America
- U.S
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia Pacific
- Rest of the World
- Brazil
- South Africa
- Saudi Arabia
- United Arab Emirates
- Others
Some of the key questions answered by the report are:
· What was the market size in 2017 and forecast from 2017 to 2022?
· What will be the industry market growth from 2017 to 2022?
· What are the major drivers, restraints, opportunities, challenges, and industry trends and their impact on the market forecast?
· What are the major segments leading the market growth and why?
· Which are the leading players in the market and what are the major strategies adopted by them to sustain the market competition?
Market Classification
- Biodefense Market , By Product, Estimates and Forecast, 2012-2022 ($Million)
- Anthrax
- Smallpox
- Botulism
- Radiation/ nuclear defense
- Other Products
- Biodefense Market , By Region, Estimates and Forecast, 2012-2022 ($Million)
- North America
- North America Biodefense Market , By Country
- North America Biodefense Market , By Product
- U.S. Biodefense Market , By Product
- Canada Biodefense Market , By Product
- Mexico Biodefense Market , By Product
-
- Europe
- Europe Biodefense Market , By Country
- Europe Biodefense Market , By Product
- Germany Biodefense Market , By Product
- France Biodefense Market , By Product
- UK Biodefense Market , By Product
- Italy Biodefense Market , By Product
- Spain Biodefense Market , By Product
- Rest of Europe Biodefense Market , By Product
-
- Asia-Pacific
- Asia-Pacific Biodefense Market , By Country
- Asia-Pacific Biodefense Market , By Product
- Japan Biodefense Market , By Product
- Australia Biodefense Market , By Product
- India Biodefense Market , By Product
- South Korea Biodefense Market , By Product
- Rest of Asia-Pacific Biodefense Market , By Product
- Asia-Pacific
-
- Rest of the World
- Rest of the World Biodefense Market , By Country
- Rest of the World Biodefense Market , By Product
- Brazil Biodefense Market , By Product
- South Africa Biodefense Market , By Product
- Saudi Arabia Biodefense Market , By Product
- Turkey Biodefense Market , By Product
- United Arab Emirates Biodefense Market , By Product
- Others Biodefense Market , By Product
- Rest of the World
Table of Contents
1. Introduction
1.1. Report Description
1.2. Research Methodology
1.2.1. Secondary Research
1.2.2. Primary Research
2. Executive Summary
2.1. Key Highlights
3. Market Overview
3.1. Introduction
3.1.1. Market Definition
3.1.2. Market Segmentation
3.2. Market Dynamics
3.2.1. Drivers
3.2.1.1. Presence of Favorable Government Initiatives
3.2.1.2. Emergency Use Authorization of Medical Products
3.2.2. Restraints
3.2.2.1. Low Penetration in Developing and Underdeveloped Countries
3.2.3. Opportunities
3.2.3.1. Emerging Markets to Offer Lucrative Growth Opportunities
4. Biodefense Market by Product
4.1. Introduction
4.2. Biodefense Market Assessment and Forecast, by Product, 2012-2022
4.3. Anthrax
4.3.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.4. Smallpox
4.4.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.5. Botulism
4.5.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.6. Radiation/Nuclear
4.6.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.7. Other Products
4.7.1. Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4. Biodefense Market by Region
4.4. Introduction
4.5. Biodefense Market Assessment and Forecast, by Region, 2012-2022 ($Million)
4.6. North America
4.6.6. Market Assessment and Forecast, by Country, 2012-2022 ($Million)
4.6.7. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.6.8. U.S.
4.6.8.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.6.9. Canada
4.6.9.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.6.10. Mexico
4.6.10.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7. Europe
4.7.6. Market Assessment and Forecast, by Country, 2012-2022 ($Million)
4.7.7. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.8. Germany
4.7.8.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.9. France
4.7.9.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.10. UK
4.7.10.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.11. Italy
4.7.11.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.12. Spain
4.7.12.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.7.13. Rest of Europe
4.7.13.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8. Asia-Pacific
4.8.6. Market Assessment and Forecast, by Country, 2012-2022 ($Million)
4.8.7. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.8. Japan
4.8.8.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.9. China
4.8.9.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.10. Australia
4.8.10.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.11. India
4.8.11.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.12. South Korea
4.8.12.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.8.13. Rest of Asia-Pacific
4.8.13.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9. Rest of the World
4.9.6. Market Assessment and Forecast, by Country, 2012-2022 ($Million)
4.9.7. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.8. Brazil
4.9.8.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.9. Turkey
4.9.9.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.10. Saudi Arabia
4.9.10.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.11. South Africa
4.9.11.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.12. United Arab Emirates
4.9.12.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
4.9.13. Others
4.9.13.1. Market Assessment and Forecast, by Product, 2012-2022 ($Million)
5. Company Profiles
6.1. Xoma Corporation
6.1.1. Business Overview
6.1.2. Product Portfolio
6.1.3. Key Financials
6.1.4. Strategic Developments
6.2. PharmaAthene
6.2.1. Business Overview
6.2.2. Product Portfolio
6.2.3. Key Financials
6.2.4. Strategic Developments
6.3. Emergent Biosolutions
6.3.1. Business Overview
6.3.2. Product Portfolio
6.3.3. Key Financials
6.3.4. Strategic Developments
6.4. Dynavax Technologies, Inc.
6.4.1. Business Overview
6.4.2. Product Portfolio
6.4.3. Key Financials
6.4.4. Strategic Developments
6.5. SIGA Technologies
6.5.1. Business Overview
6.5.2. Product Portfolio
6.5.3. Strategic Developments
6.6. Elusys Therapeutics
6.6.1. Business Overview
6.6.2. Product Portfolio
6.6.3. Strategic Developments
6.7. Ichor Medical Systems, Inc.
6.7.1. Business Overview
6.7.2. Product Portfolio
6.7.3. Strategic Developments
6.8. DynPort Vaccine Company LLC
6.8.1. Business Overview
6.8.2. Product Portfolio
6.8.3. Strategic Developments
6.9. Cleveland BioLabs, Inc.
6.9.1. Business Overview
6.9.2. Product Portfolio
6.9.3. Strategic Developments
6.10. Bavarian Nordic
6.10.1. Business Overview
6.10.2. Product Portfolio
6.10.3. Strategic Developments
6.11. Achaogen
6.11.1. Business Overview
6.11.2. Product Portfolio
6.11.3. Key Financials
6.11.4. Strategic Developments
List of Tables
List of Tables
Table 1.Biodefense Market by Product ($Million), 2012-2022
Table 2.Anthrax Market, by Type ($Million), 2012-2022
Table 3.Smallpox Market, by Region ($Million), 2012-2022
Table 4.Botulism Market, by Region ($Million), 2012-2022
Table 5.Radiation/ nuclear defense Market, by Region ($Million), 2012-2022
Table 6.Other Products Market, by Region ($Million), 2012-2022
Table 7.North America Biodefense Market by Country, 2012-2022 ($Million)
Table 8.North America Biodefense Market, by Product2012-2022 ($Million)
Table 9.U.S.Biodefense Market, by Product2012-2022 ($Million)
Table 10.Canada Biodefense Market, by Product2012-2022 ($Million)
Table 11.Mexico Biodefense Market, by Product2012-2022 ($Million)
Table 12.Europe Biodefense Market by Country, 2012-2022 ($Million)
Table 13.Europe Biodefense Market, by Product2012-2022 ($Million)
Table 14.Germany Biodefense Market, by Product2012-2022 ($Million)
Table 15.France Biodefense Market, by Product2012-2022 ($Million)
Table 16.UK Biodefense Market, by Product2012-2022 ($Million)
Table 17.Italy Biodefense Market, by Product2012-2022 ($Million)
Table 18.Spain Biodefense Market, by Product2012-2022 ($Million)
Table 19.Rest of Europe Biodefense Market, by Product2012-2022 ($Million)
Table 20.Asia-Pacific Biodefense Market by Country, 2012-2022 ($Million)
Table 21.Asia-Pacific Biodefense Market, by Product2012-2022 ($Million)
Table 22.Japan Biodefense Market, by Product2012-2022 ($Million)
Table 23.China Biodefense Market, by Product2012-2022 ($Million)
Table 24.Australia Biodefense Market, by Product2012-2022 ($Million)
Table 25.India Biodefense Market, by Product2012-2022 ($Million)
Table 26.South Korea Biodefense Market, by Product2012-2022 ($Million)
Table 27.Rest of Asia-Pacific Biodefense Market, by Product2012-2022 ($Million)
Table 28.Rest of the World Biodefense Market by Country, 2012-2022 ($Million)
Table 29.Rest of the World Biodefense Market, by Product2012-2022 ($Million)
Table 30.Brazil Biodefense Market, by Product2012-2022 ($Million)
Table 31.Turkey Biodefense Market, by Product2012-2022 ($Million)
Table 32.Saudi Arabia Biodefense Market, by Product2012-2022 ($Million)
Table 33.South Africa Biodefense Market, by Product2012-2022 ($Million)
Table 34.United Arab Emirates Biodefense Market, by Product2012-2022 ($Million)
Table 35.Others Biodefense Market, by Product2012-2022 ($Million)
Table 36.Tosoh Corporation: Key Strategic Developments, 2017-2017
Table 37.Arkema Group: Key Strategic Developments, 2017-2017
Table 38.BASF SE: Key Strategic Developments, 2017-2017
Table 39.Interra Global Corporation: Key Strategic Developments, 2017-2017
Table 40.UOP LLC: Key Strategic Developments, 2017-2017
Table 41.Zeochem AG: Key Strategic Developments, 2017-2017
Table 42.Grace Catalysts Technologies: Key Strategic Developments, 2017-2017
Table 43.Chemiewerk Bad Köstritz: Key Strategic Developments, 2017-2017
Table 44.Tricat Group: Key Strategic Developments, 2017-2017
Table 45.KNT Group: Key Strategic Developments, 2017-2017
Table 46.Zeox Corporation: Key Strategic Developments, 2017-2017
List of Figures
List of Figures
Figure 1.Biodefense Market Share, by Product, 2017 & 2025
Figure 2Biodefense Market by Region, 2017, ($Million)
Figure 3.Xoma Corporation: Net Revenues, 2017-2017 ($Million)
Figure 4.Xoma Corporation: Net Revenue Share, by Segment, 2017
Figure 5.Xoma Corporation: Net Revenue Share, by Geography, 2017
Figure 6.PharmAthene: Net Revenues, 2017-2017 ($Million)
Figure7.PharmAthene: Limited Net Revenue Share, by Segment, 2017
Figure8.PharmAthene: Net Revenue Share, by Geography, 2017
Figure9.Emergent Biosolutions: Net Revenues, 2017-2017 ($Million)
Figure10.Emergent Biosolutions: Net Revenue Share, by Segment, 2017
Figure 11.Emergent Biosolutions: Net Revenue Share, by Geography, 2017
Figure 12.Dynavax Technologies Inc.: Net Revenues, 2017-2017 ($Million)
Figure 13.Dynavax Technologies Inc.: Net Revenue Share, by Segment, 2017
Figure 14.Dynavax Technologies Inc.: Net Revenue Share, by Geography, 2017
Figure 12.Achaogen: Net Revenues, 2017-2017 ($Million)
Figure 13.Achaogen: Net Revenue Share, by Segment, 2017
Figure 14.Achaogen: Net Revenue Share, by Geography, 2017
Research Methodology
We use both primary as well as secondary research for our market surveys, estimates and for developing forecast. Our research process commence by analyzing the problem which enable us to design the scope for our research study. Our research process is uniquely designed with enough flexibility to adjust according to changing nature of products and markets, while retaining core element to ensure reliability and accuracy in research findings. We understand both macro and micro-economic factors to evaluate and forecast different market segments.
Data Mining
Data is extensively collected through various secondary sources such as annual reports, investor presentations, SEC filings, and other corporate publications. We also refer trade magazines, technical journals, paid databases such as Factiva and Bloomberg, industry trade journals, scientific journals, and social media data to understand market dynamics and industry trends. Further, we also conduct primary research to understand market drivers, restraints, opportunities, challenges, and competitive scenario to build our analysis.
Data Collection Matrix
|
Data Collection Matrix |
Supply Side |
Demand Side |
|
Primary Data Sources |
|
|
|
Secondary Data Sources |
|
|
Market Modeling and Forecasting
We use epidemiology and capital equipment-based models to forecast market size of different segments at country and regional level.
- Epidemiology-based Forecasting Model: This method uses epidemiology data gathered through various publications and from physicians to estimate population of patients, flow of treatment of individual disease and therapies. The data collected through this method includes statics on incidence of disease, population suffering from disease, and treatment population. This method is used to understand:
- Number of patients for particular device or medical procedure and
- Repeated use of particular device depending on health and condition of patient
- Capital-based Forecasting Model: This method of forecasting is based on number of replacements, installed-based and new sales of capital equipment used in various healthcare and diagnostic centers. These three parameters are calculated and forecast is developed. Installation base is calculated as average number of units per facility; while sales for particular year is calculated from number of new and replace units. Secondary data is collected through various supply chain intermediaries and opinion leaders to arrive at installation and sales rate. These techniques help our analysts in validating market and developed market estimates and forecast.
We do forecast on basis of several parameters such as market drivers, market opportunities, industry trends government regulations, raw materials supply and trade dynamics to ensure relevance of forecast with market scenario. With increasing need to granulized information, we used bottom-up methodology for forecasting where we evaluate each regional segment differently and combined all forecast to develop final market forecast.
Data Validation
We believe primary research is a very important tool in analyzing and forecasting different markets. In order to make sure accuracy of our findings, our team conducts primary interviews at every stage of research to gain deep insights into current business environment and future trends and key developments in market. This includes use of various methods such as telephonic interviews, focus groups, face to face interviews and questionnaires to validate our research from all aspects. We validate our data through primary research from key industry leaders such as CEO, product managers, marketing managers, suppliers, distributors, and consumers are frequently interviewed. These interviews provide valuable insights which help us to have better market understanding besides validating our estimates and forecast.
Data Triangulation
Industry Analysis
|
Qualitative Data |
Quantitative Data (2017-2025) |
|
|